What are the recommended first‑line testosterone replacement options, dosing regimens, and monitoring guidelines?

Testosterone Replacement Therapy: First-Line Options, Dosing, and Monitoring

Transdermal testosterone gel should be the preferred first-line formulation for initiating testosterone replacement therapy, as it provides stable physiologic levels with lower risk of erythrocytosis compared to intramuscular injections. 1

First-Line Testosterone Formulations

Transdermal Preparations (Preferred)

• Transdermal testosterone gel is recommended as the initial treatment option for most men with hypogonadism 1
• Transdermal formulations produce more stable serum testosterone levels and carry significantly lower risk of erythrocytosis (3-18%) compared to intramuscular injections (up to 44%) 2
• Gel dosing typically starts at 40-50 mg/day (delivering 5 mg/day systemically), with higher doses of 100 mg/day (delivering 10 mg/day) available for inadequate response 2

Intramuscular Injections (Alternative)

• Intramuscular testosterone enanthate or cypionate can be used when transdermal therapy is not suitable 2
• Injections are administered every 2-3 weeks, with peak levels occurring 2-5 days post-injection and return to baseline at 10-14 days 2
• The primary advantage is lower cost ($156.24 annually vs. $2,135.32 for transdermal) 2
• Major disadvantages include "roller coaster" symptom fluctuations, injection pain, and substantially higher erythrocytosis risk (43.8% in studies) 2

Baseline Evaluation Requirements

Before initiating testosterone therapy, the following assessments are mandatory 2:

• Serum testosterone levels (morning, fasting, repeated to confirm diagnosis)
• Prostate-specific antigen (PSA) measurement
• Digital rectal examination of the prostate
• Hematocrit or hemoglobin levels
• Baseline voiding history or standardized questionnaire for urinary symptoms
• History of sleep apnea
• Prostate biopsy if PSA >4.0 ng/mL or abnormal digital rectal examination 2

Monitoring Protocol

Initial Follow-Up (1-2 Months)

• Assess efficacy and adjust dosing for suboptimal response 2
• For transdermal gel, measure testosterone at both +2 hours (peak) and +23 hours (trough) after application to ensure adequate levels throughout the day 3
• Target serum testosterone >3.5 ng/mL at both time points for optimal symptom control 3

Regular Monitoring (Every 3-6 Months First Year, Then Annually)

The following parameters must be monitored 2:

• Serum testosterone levels to maintain physiologic range (500-800 ng/dL) 4
• Hematocrit or hemoglobin - most critical safety parameter given erythrocytosis risk
• PSA levels with specific thresholds for biopsy consideration
• Digital rectal examination
• Assessment of urinary symptoms
• Evaluation for sleep apnea exacerbation or gynecomastia

Hematocrit Management

• Monitor closely as erythrocytosis is the most common dose-related adverse effect 2, 4
• If hematocrit exceeds 52%, consider dose reduction, temporary withholding of testosterone, therapeutic phlebotomy, or blood donation 2
• Hematocrit >48-50% represents a relative contraindication for continuing therapy 1

PSA Monitoring and Prostate Biopsy Thresholds

Multiple approaches exist for PSA monitoring, with the most conservative and clinically prudent being 2:

• Perform biopsy if PSA rises by ≥1.0 ng/mL in any single year
• If PSA increases by 0.7-0.9 ng/mL in one year, repeat PSA in 3-6 months and biopsy if any further increase
• Perform biopsy if PSA exceeds 4.0 ng/mL
• Perform biopsy if digital rectal examination shows new nodule, asymmetry, or increased firmness

This approach is more aggressive than some guidelines but is justified given the concern about unmasking previously occult prostate cancer during the first year of treatment 2.

Absolute Contraindications

Testosterone therapy must not be initiated in men with 1:

• Untreated prostate cancer
• Untreated breast cancer
• Severe heart failure

Key Safety Considerations

Cardiovascular Safety

• Large-scale evidence from the TRAVERSE trial demonstrates that testosterone therapy does not increase risk of major adverse cardiovascular events, even in high-risk patients 5, 6
• Earlier concerns about myocardial infarction and stroke risk have been refuted by recent high-quality data 6

Prostate Cancer Risk

• No compelling evidence suggests testosterone therapy increases prostate cancer risk 2
• Proper monitoring with PSA and digital rectal examination promotes early diagnosis of any unmasked cancers 2
• Prostate volume increases during the first 6 months of therapy but rarely causes clinically significant voiding symptoms 2

Common Pitfalls to Avoid

• Do not use oral testosterone preparations (except testosterone undecanoate where available) due to hepatotoxicity risk 2
• Do not rely solely on peak testosterone levels with transdermal gel - trough levels at +23 hours are equally important to ensure adequate coverage 3
• Do not continue therapy if hematocrit exceeds 52% without intervention 2
• Do not dismiss small PSA increases - rises of 0.7-0.9 ng/mL warrant close follow-up 2